CluePoints has announced the launch of its latest application, Medical & Safety Review (MSR), designed to revolutionize the ...

Galderma today announced that it will present new data from the ARCADIA and OLYMPIA clinical trial programs investigating ...

In September 2024, the U.S. Food and Drug Administration (FDA) issued three guidance documents to support different clinical ...

No new safety concerns and consistent safety profiles were observed for long-term risankizumab use in patients with psoriasis and PsA.

Riociguat is generally safe and effective for PAH patients with coexisting cardiac and metabolic conditions, a trials ...

Italy: A recent analysis of the FDA Adverse Event Reporting System (FAERS) database has provided new insights into the safety ...

Cassava's financial challenges and data integrity concerns remain critical. Learn why SAVA stock is rated a strong sell given ...

Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...

BUFFALO, NY / ACCESSWIRE / September 27, 2024 / POP Biotechnologies (POP BIO), a Buffalo, NY-based biopharmaceutical company, ...

Recent research easing suicidality concerns about GLP-1s and suggesting potential psychiatric benefit has led to a call for ...

FDA has lifted the clinical hold on Biomea Fusion's BMF-219 trials for type 1 and type 2 diabetes following a safety review, ...

A meta-analysis reveals gamified digital mental health interventions effectively reduce depression and ADHD in youth, ...